# Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure

> **NCT01748240** · PHASE2 · TERMINATED · sponsor: **Groupe Francophone des Myelodysplasies** · enrollment: 21 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine and oral vorinostat

## Key facts

- **NCT ID:** NCT01748240
- **Lead sponsor:** Groupe Francophone des Myelodysplasies
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03
- **Primary completion:** 2013-10
- **Final completion:** 2015-07
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** inefficiency
- **Last updated:** 2019-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01748240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01748240, "Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01748240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*